Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting

References

• Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy induced nausea and vomiting. Nejm. 2016;374:1356–1367.
   PubMed Web of Science ®Google Scholar
• Jordan K, Gralla R, Jahn F, et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Europ J Pharmacol. 2014;722:197–202.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy –induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–4119.
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.
   PubMed Web of Science ®Google Scholar
• Grelot L, Miller AD. Vomiting: its ins and outs. News Physiol Sci. 1994;9:142–146.
   Google Scholar
• Janelsins MC, Tejani MA, Kamen C, et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013;14:757–766.
   PubMed Web of Science ®Google Scholar
• Chu CC, Hsing CH, Shieh JP, et al. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol. 2014;722:48–54.
   PubMed Web of Science ®Google Scholar
• Allen A, Crome P, Davie CC, et al. The pharmacokinetics of granisetron, a 5-HT3 antagonist in healthy young and elderly volunteers. Eur J Clin Pharmacol. 1995;48:519–520.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.drugs.com/newdrugs/heron-therapeutics-announces-fda-approval-sustol-granisetron-extended-release-prevention-4420.html
   Google Scholar
• Blower PR. Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer. 2003;11:93–100.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Nelson DR. Selective and functional 5-hydroxytryptamine 3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol. 1989;159:113–124.
   PubMed Web of Science ®Google Scholar
• Blower P. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer. 1990;26(Suppl):S8–11.
   PubMedGoogle Scholar
• Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990;188:301–312.
   PubMed Web of Science ®Google Scholar
• Gebauer A, Merger M, Kilbinger H. Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:137–140.
   PubMed Web of Science ®Google Scholar
• Endo T, Ogawa T, Hamaue N, et al. Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets. Res Commun Mol Pathol Pharmacol. 1998;100:243–253.
   PubMed Web of Science ®Google Scholar
• Castejon AM, Paez X, Hernandez L, et al. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther. 1999;291:960–966.
   PubMed Web of Science ®Google Scholar
• Allen A, Asgill CC, Pierce DM, et al. Pharmacokinetics and tolerability of ascending dose of granisetron, a novel 5-HT3 antagonist, in healthy human subjects. Eur J Clin Pharmacol. 1994;46:159–162.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Raina V, Lewis C, et al. Pharmacokinetics and anti- emetic efficacy of BLR43694 a new selective 5HT-3 antagonist. Br J Pharmacol. 1988;58:651–653.
   Google Scholar
• Wada I, Takeda T, Sato M, et al. Pharmacokinetics of granisetron in adults and children with malignant diseases. Biol Pharm Bull. 2001;24:432–435.
   PubMed Web of Science ®Google Scholar
• Carmichael J, Cantwell BM, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol. 1989;24:45–49.
   PubMed Web of Science ®Google Scholar
• Craft AW, Price L, Eden OB, et al. Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol. 1995;25:28–32.
   PubMedGoogle Scholar
• Grimwood S, Hartig PR. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther. 2009;122:281–301.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugiura M, Higo K, et al. Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol. 2004;54:185–190.
   PubMed Web of Science ®Google Scholar
• Endo J, Iihara H, Yamada M, et al. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy. Anticancer Res. 2012;32:3939–3947.
   PubMed Web of Science ®Google Scholar
• Corrigan BW, Nicholls B, Thakrar B, et al. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos. 1999;27:110–112.
   PubMed Web of Science ®Google Scholar
• Howell J, Smeets J, Drenth HJ, et al. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. 2009;15:223–231.
   PubMedGoogle Scholar
• Sancuso (granisetron transdermal system) [package insert]. Bedminster (NJ): ProStrakan, Inc.; 2008.
   Google Scholar
• Mason JW, Selness DS, Moon TE, et al. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res. 2012;18:2913–2921.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.sustol.com/public/pdfs/PI.pdf
   Google Scholar
• Gabrail N, Yanagihara R, Spaczyński M, et al. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Manag Res. 2015;7:83–92.
   PubMed Web of Science ®Google Scholar
• Bloomer JC, Baldwin SJ, Smith GJ, et al. Characterisation of the cytochrome P450 enzymes involvedin the in vitro metabolism of granisetron. Br J Clin Pharmac. 1994;38:557–566.
   PubMed Web of Science ®Google Scholar
• Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. 2002;8:405–414.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Ariyoshi N, Okada K, et al. CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005;6:469–480.
   PubMed Web of Science ®Google Scholar
• Palmer R. Efficacy and safety of granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function. Semin Oncol. 1994;21(Suppl 5):22–25.
   PubMedGoogle Scholar
• Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol. 2006;19:606–611.
   PubMed Web of Science ®Google Scholar
• Hassan BA, Yusoff ZB. Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev. 2011;12:185–191.
   PubMedGoogle Scholar
• Bustos ML, Zhao Y, Chen H, et al. Polymorphisms in CYP1A1 and CYP3A5 genes contribute to the variability in granisetron clearance and exposure in pregnant women with nausea and vomiting. Pharmacotherapy. 2016;36:1238–1244.
   PubMed Web of Science ®Google Scholar
• Tsuji D, Yokoi M, Suzuki K, et al. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J. 2016 May 31. DOI:10.1038/tpj.2016.38.
   Web of Science ®Google Scholar
• Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005;78:619–626.
   PubMed Web of Science ®Google Scholar
• Tsuji D, Kim YI, Nakamichi H, et al. Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients. Drug Metab Pharmacokinet. 2013;28:299–304.
   PubMed Web of Science ®Google Scholar
• Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy in not arythmogenic: results of a pilot study. Eur J Cancer. 2003;39:927–931.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol. 1995;35:278–282.
   PubMed Web of Science ®Google Scholar
• Jantunen IT, Kataja VV, Muhonen TT, et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol. 1996;37:502–504.
   PubMed Web of Science ®Google Scholar
• Carmichael J, Harris AL. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol. 2004;53:123–128.
   PubMed Web of Science ®Google Scholar
• Carmichael J, Philip PA, Forfar C, et al. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol. 1995;37:134–138.
   PubMed Web of Science ®Google Scholar
• Quraishi SA, Schuler GH, Janicki PK. 5 HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalities. J Clin Anesth. 2011;23:297–302.
   PubMed Web of Science ®Google Scholar
• Al Harbi M, Al Rifai D, Al Habeeb H, et al. A case of granisetron associated intraoperative cardiac arrest. Middle East J Anaesthesiol. 2016;23:475–478.
   PubMedGoogle Scholar
• Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol. 2005;28:201–204.
   PubMed Web of Science ®Google Scholar
• Pinarli FG, Elli M, Dagdemir A, et al. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer. 2006;47:567–571.
   PubMed Web of Science ®Google Scholar
• Cakir FB, Yapar O, Canpolat C, et al. Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial. Support Care Cancer. 2012;20:2451–2457.
   PubMed Web of Science ®Google Scholar
• Julius JM, Tindall A, Moise KJ, et al. Evaluation of the maternal-fetal transfer of granisetron in an ex vivo placenta perfusion model. Reprod Toxicol. 2014;49:43–47.
   PubMed Web of Science ®Google Scholar
• Smith JA, Julius JM, Gaikwada A, et al. Evaluating the potential effect on fetal tissue after exposure to granisetron during pregnancy. Reprod Toxicol. 2015;53:92–98.
   PubMed Web of Science ®Google Scholar
• Navari RM. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016;15:343–356.
   PubMed Web of Science ®Google Scholar
• Dupuis LL, Boodhan S, Holdsworth M, et al. Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60:1073–1082.
   PubMed Web of Science ®Google Scholar
• Carmichael J, Cantwell BM, Edwards CM, et al. The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin. Bmj. 1988;297(6641):110–111.
   PubMedGoogle Scholar
• Tsuji D, Kim YI, Taku K, et al. Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial. Support Care Cancer. 2012;20:1057–1064.
   PubMed Web of Science ®Google Scholar
• Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer. 1990;26(Suppl 1):S23–7.
   PubMed Web of Science ®Google Scholar
• Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. Eur J Cancer. 1990;26(Suppl 1):S15–9.
   PubMed Web of Science ®Google Scholar
• Riviere A. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy.TheGranisetron Study Group. Br J Cancer. 1994;69:967–971.
   PubMed Web of Science ®Google Scholar
• Perez EA, Navari RM, Kaplan HG, et al. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997;5:31–37.
   PubMed Web of Science ®Google Scholar
• Joss RA, Dott CS. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group. Eur J Cancer. 1993;29A(Suppl 1):S22–9.
   PubMedGoogle Scholar
• Warr D, Wilan A, Venner P, et al. A randomized, double- blind comparison of granisetron with high –dose metoclopramide, dexamethasone and diphenhydramine for cisplatin- induced emesis. An NCI Canada clinical trials group phase II trial. Eur J Cancer. 1992;29A(1):33–36.
   PubMed Web of Science ®Google Scholar
• Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti- emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic- induced emesis. The granisetron study group. Eur J Cancer. 1990;26Suppl 1:S28–32.
   Google Scholar
• Hamadani M, Chaudhary L, Awan FT, et al. Management of platinum – based chemotherapy- induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? J Oncol Pharm Pract. 2007;13:69–75.
   PubMedGoogle Scholar
• Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy – induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994;74:1945–1952.
   PubMed Web of Science ®Google Scholar
• Herrington JD, Kwan P, Young RR, et al. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy. 2000;20:1318–1323.
   PubMed Web of Science ®Google Scholar
• Barrajon E, De Las Peñas R. Randomized double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost- benefit analysis. Support Care Cancer. 2000;8:323–333.
   PubMed Web of Science ®Google Scholar
• Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology. 1994;51:113–118.
   PubMed Web of Science ®Google Scholar
• Stewart A, McQuade B, Cronje JD, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology. 1995;52:202–210.
   PubMed Web of Science ®Google Scholar
• Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995;13:1242–1248.
   PubMed Web of Science ®Google Scholar
• Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998;16:754–760.
   PubMed Web of Science ®Google Scholar
• Jordan K, Hinke A, Grothey A, et al. Granisetron versus tropisetron for prophylaxis of acute chemotherapy induced emesis: a pooled analysis. Support Care Cancer. 2005;13:26–31.
   PubMed Web of Science ®Google Scholar
• Jordan K, Hinke A, Grothey A, et al. A meta- analysis comparing the efficacy of four 5-HT3- receptor antagonists for acute chemotherapy – induced emesis. Support Care Cancer. 2007;15:1023–1033.
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med. 1995;5; 332:1–5.
   Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–124.
   PubMed Web of Science ®Google Scholar
• Ueda H, Shimono C, Nishimura T, et al. Palonosetron exhibits higher total control rate compared to first-generation serotonin antagonists and improves appetite in delayed-phase chemotherapy-induced nausea and vomiting. Mol Clin Oncol. 2014;2:375–379.
   PubMedGoogle Scholar
• Suzuki K, Yamanaka T, Hashimoto H, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016;27:1601–1606.
   PubMed Web of Science ®Google Scholar
• Oyama K, Fushida S, Kaji M, et al. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Int J Clin Oncol. 2016;21:483–490.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Barbour SY, Morrow GR, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22:469–477.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Blondal E, Veroniki AA, et al. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med. 2016;14(1):216.
   PubMed Web of Science ®Google Scholar
• Broder MS, Faria C, Powers A, et al. The impact of 5-HT3RA use on cost and utilization in patients with chemotherapy-induced Nausea and Vomiting: systematic review of the literature. Am Health Drug Benefits. 2014;7:171–182.
   PubMedGoogle Scholar
• Hesketh PJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2016;34:381–386.
   PubMed Web of Science ®Google Scholar
• Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19:1609–1617.
   PubMed Web of Science ®Google Scholar
• Kim JE, Hong YS, Lee JL, et al. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer. 2015;23:1769–1777.
   PubMed Web of Science ®Google Scholar
• Yang LQ, Sun XC, Qin SK, et al. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. Chin Clin Oncol. 2016;5:79.
   PubMed Web of Science ®Google Scholar
• Boccia R, O’Boyle E, Cooper W. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy. BMC Cancer. 2016;16:166.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Cooper W, O’Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, non-inferiority phase 3 trial. Support Care Cancer. 2015;23:723–732.
   PubMed Web of Science ®Google Scholar
• Schnadig ID, Agajanian R, Dakhil C, et al. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol. 2016;12:1469–1481.
   PubMed Web of Science ®Google Scholar
• Seol YM, Kim HJ, Choi YJ, et al. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer. 2016;24:945–952.
   PubMed Web of Science ®Google Scholar
• Blower P R. 5-ht3 receptor antagonists and the cytochrome p450 system: clinical implications. the Cancer journal. 2002;8:405-414. DOI: 10.1097/00130404-200209000-00012
   PubMed Web of Science ®Google Scholar
• Youlten L. The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers. J Pharm Pharmacol. 2004;56:169–175.
   PubMed Web of Science ®Google Scholar
• Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetic of ondansetron and granisetron in healthy subjects. Clin Ther. 2003;25:1407–1419.
   PubMed Web of Science ®Google Scholar
• Adams LM, Johnson B, Zhang K, et al. Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer. 2009;17:1187–1193.
   PubMed Web of Science ®Google Scholar
• Sorscher SM. Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist. J Psychopharmacol. 2002;16:191.
   PubMed Web of Science ®Google Scholar
• Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. J Clin Anesth. 2012;24:251–252.
   PubMed Web of Science ®Google Scholar
• Mir O, Durand JP, Boudou-Rouquette P, et al. Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case–control study. Support Care Cancer. 2012;20:2235–2239.
   PubMed Web of Science ®Google Scholar